Literature DB >> 26499105

Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Mark A Castanares1, Ben T Copeland2, Wasim H Chowdhury3, Minzhi M Liu3, Ronald Rodriguez3, Martin G Pomper2, Shawn E Lupold3, Catherine A Foss2.   

Abstract

BACKGROUND: The LNCaP cell line was originally isolated from the lymph node of a patient with metastatic prostate cancer. Many cell lines have been derived from LNCaP by selective pressures to study different aspects of prostate cancer progression. When injected subcutaneously into male athymic nude mice, LNCaP and its derivatives rarely metastasize.
METHODS: Here, we describe the characteristics of a new LNCaP derivative, JHU-LNCaP-SM, which was generated by long term passage in normal cell culture conditions.
RESULTS: Short tandem repeat (STR) analysis and genomic sequencing verified JHU-LNCaP-SM derivation from parental LNCaP cells. JHU-LNCaP-SM cells express the same mutated androgen receptor (AR) but unlike LNCaP, are no longer androgen dependent for growth. The cells demonstrate an attenuated androgen responsiveness in transcriptional assays and retain androgen sensitive expression of PSA, AR, and PSMA. Unlike parental LNCaP, JHU-LNCaP-SM cells quickly form subcutaneous tumors in male athymic nude mice, reliably metastasize to the lymph nodes and display a striking intra-tumoral and spreading hemorrhagic phenotype as tumor xenografts.
CONCLUSIONS: The JHU-LNCaP-SM cell line is a new isolate of LNCaP, which facilitates practical, preclinical studies of spontaneous metastasis of prostate cancer through lymphatic tissues.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  JHU-LNCaP-SM; PSMA; androgen; lymph node; metastasis

Mesh:

Year:  2015        PMID: 26499105      PMCID: PMC4729204          DOI: 10.1002/pros.23115

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  38 in total

1.  Biologists tackle cells' identity crisis.

Authors:  Alla Katsnelson
Journal:  Nature       Date:  2010-06-03       Impact factor: 49.962

Review 2.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

3.  Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis.

Authors:  Sebastian Mannweiler; Peter Amersdorfer; Slave Trajanoski; Jonathan A Terrett; David King; Gabor Mehes
Journal:  Pathol Oncol Res       Date:  2008-09-18       Impact factor: 3.201

4.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Authors:  Takahito Nakajima; Makoto Mitsunaga; Neil H Bander; Warren D Heston; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2011-07-27       Impact factor: 4.774

Review 5.  Drug discovery in prostate cancer mouse models.

Authors:  Kenneth C Valkenburg; Kenneth J Pienta
Journal:  Expert Opin Drug Discov       Date:  2015-06-01       Impact factor: 6.098

6.  LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.

Authors:  G N Thalmann; R A Sikes; T T Wu; A Degeorges; S M Chang; M Ozen; S Pathak; L W Chung
Journal:  Prostate       Date:  2000-07-01       Impact factor: 4.104

7.  Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients.

Authors:  Yoshikuni Yonenaga; Akira Mori; Hisashi Onodera; Seiichi Yasuda; Hideaki Oe; Akihisa Fujimoto; Tsuyoshi Tachibana; Masayuki Imamura
Journal:  Oncology       Date:  2005-08-24       Impact factor: 2.935

Review 8.  The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity.

Authors:  G J van Steenbrugge; C J van Uffelen; J Bolt; F H Schröder
Journal:  J Steroid Biochem Mol Biol       Date:  1991       Impact factor: 4.292

9.  Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

Authors:  Sangeeta R Banerjee; Catherine A Foss; Mark Castanares; Ronnie C Mease; Youngjoo Byun; James J Fox; John Hilton; Shawn E Lupold; Alan P Kozikowski; Martin G Pomper
Journal:  J Med Chem       Date:  2008-07-19       Impact factor: 7.446

10.  Pericytes limit tumor cell metastasis.

Authors:  Xiaojie Xian; Joakim Håkansson; Anders Ståhlberg; Per Lindblom; Christer Betsholtz; Holger Gerhardt; Henrik Semb
Journal:  J Clin Invest       Date:  2006-02-09       Impact factor: 14.808

View more
  12 in total

1.  Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Authors:  Ben T Copeland; Hassan Shallal; Chentian Shen; Kenneth J Pienta; Catherine A Foss; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

Review 2.  Development of patient-derived xenograft models of prostate cancer for maintaining tumor heterogeneity.

Authors:  Changhong Shi; Xue Chen; Dengxu Tan
Journal:  Transl Androl Urol       Date:  2019-10

3.  Efficacy of PACE4 pharmacotherapy in JHU-LNCaP-SM preclinical model of androgen independent prostate cancer.

Authors:  Nawel Mekdad; Thi Minh Hue Tran; Roxane Desjardins; Anna Kwiatkowska; Frédéric Couture; Robert Day
Journal:  Sci Rep       Date:  2022-10-19       Impact factor: 4.996

4.  Tuning Pharmacokinetics to Improve Tumor Accumulation of a Prostate-Specific Membrane Antigen-Targeted Phototheranostic Agent.

Authors:  Kara M Harmatys; Marta Overchuk; Juan Chen; Lili Ding; Ying Chen; Martin G Pomper; Gang Zheng
Journal:  Bioconjug Chem       Date:  2018-10-29       Impact factor: 4.774

5.  A Novel Tanshinone Analog Exerts Anti-Cancer Effects in Prostate Cancer by Inducing Cell Apoptosis, Arresting Cell Cycle at G2 Phase and Blocking Metastatic Ability.

Authors:  Mengling Wang; Xueyi Zeng; Shengyou Li; Zekun Sun; Jia Yu; Chao Chen; Xiangchun Shen; Weidong Pan; Heng Luo
Journal:  Int J Mol Sci       Date:  2019-09-10       Impact factor: 5.923

6.  In situ Generated <sup>212</sup>Pb-PSMA Ligand in a <sup>224</sup>Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells.

Authors:  Vilde Y Stenberg; Asta Juzeniene; Øyvind S Bruland; Roy H Larsen
Journal:  Curr Radiopharm       Date:  2020

7.  Circulating prostate cancer cells have differential resistance to fluid shear stress-induced cell death.

Authors:  Jacob M Hope; Matthew R Bersi; Jenna A Dombroski; Andrea B Clinch; Rebecca S Pereles; W David Merryman; Michael R King
Journal:  J Cell Sci       Date:  2021-02-22       Impact factor: 5.285

8.  Proteomic analysis of human prostate cancer PC-3M-1E8 cells and PC-3M-2B4 cells of same origin but with different metastatic potential.

Authors:  Shujiang Zhang; Chengcheng Zheng; Shunheng Yao; Zhonghui Wang; Li Xu; Rongfu Yang; Xiang Meng; Jianhui Wu; Li Zhou; Zuyue Sun
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

9.  Factors that influence the androgen receptor cistrome in benign and malignant prostate cells.

Authors:  Ben T Copeland; Juan Du; Sumanta K Pal; Jeremy O Jones
Journal:  Mol Oncol       Date:  2019-10-13       Impact factor: 6.603

10.  Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation.

Authors:  Pengpeng Wu; Rong Xu; Xue Chen; Ya Zhao; Dengxu Tan; Yong Zhao; Weijun Qin; Caiqin Zhang; Xu Ge; Changhong Shi
Journal:  Aging (Albany NY)       Date:  2020-02-24       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.